BioAuxilium Thunder™ TR-FRET Cell Signaling Assays
BioAuxilium Thunder™ TR-FRET Cell Signaling Assays

Meet the experts at the heart of BioAuxilium

https://bioauxilium.com/about-us/


Dr. Jaime Padros and Mireille Caron are the co-founders of BioAuxilium and each have over 20 years of academic and industry experience. They have a renowned expertise in the design, development and manufacturing of assay kits and reagents on the most popular technology platforms available (e.g., TR-FRET, AlphaScreen®/AlphaLISA®, BRET/BRET2, FP, Aequorin and more).

Before BioAuxilium, Mireille and Jaime were Technical Project Leaders and Senior Scientists at PerkinElmer-BioSignal (Montréal), where they played key roles in the development of several commercially successful products based on TR-FRET. Since the inception of BioAuxilium in 2013, Mireille and Jaime, supported by their team of scientists, have developed and licensed hundreds of TR-FRET assay kits enabling the quantification of cellular proteins and biomarkers.

BioAuxilium is based in Montréal (Canada) and located within NEOMED’s state-of-the-art laboratories and core facilities where the company provides a wide range of product and assay development services to academic and industry research groups.


Bioauxilium is a private Canadian biotechnology company founded by seasoned scientists from PerkinElmer. The company is focused on the design, development and manufacturing of top-quality, fully-validated assay kits that simplify laboratory workflow and accelerate biomedical research. Since its inception in 2013, Bioauxilium has licensed hundreds of TR FRET assay kits enabling the quantification of cellular proteins and biomarkers. Bioauxilium’s kits are based on its proprietary THUNDER™ TR-FRET technology. They are offered at an outstanding value and are supported by expert technical support. Bioauxilium also provides on a contract basis customized services in assay development using diverse cutting-edge technologies. 


Our services: ■ Custom TR-FRET-based immunoassay kit development and manufacturing ■ Conversion of ELISAs into homogeneous immunoassays (TR-FRET, AlphaLISA) amenable to automation using your antibody pair or our “best pair” screening service ■ Custom labeling: labeling of biomolecules with lanthanides, fluorophores or biotin to build reagent tools necessary for assay development ■ Custom biochemical, cell-based and biomarker assay development using multiple technology platforms (absorbance, fluorescence, FP, TRF, TR-FRET, luminescence, AlphaScreen, AlphaLISA) ■ Assay design, development, optimization and validation for drug discovery research, from HTS to lead optimization 


PUBLICATIONS

Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
GAUTHIER N, CARON M, PEDRO L, ARCAND M, BLOUIN J, LABONTÉ A, NORMAND C, PAQUET V, RODENBROCK A, ROY M, ROULEAU N, BEAUDET L, PADRÓS J, RODRIGUEZ-SUAREZ R (2012). Journal Biomolecular Screening 17: 49-58. 

A sensitive, homogeneous, and high-throughput assay for lysine-specific histone demethylases at the H3K4 site.
WANG C, CARON M, BURDICK D, KANG Z, AULD D, HILL WA, PADRÓS J, ZHANG JH (2012). Assays and Drug Development Technologies 10: 179-186. 

Single-well monitoring of protein-protein interaction and phosphorylation-dephosphorylation events.
ARCAND M, ROBY P, BOSSÉ R, LIPARI F, PADRÓS J, BEAUDET L, MARCIL A, DAHAN S (2010). Biochemistry ‍49: 3213-3215. 

Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
PEDRO L, PADRÓS J, BEAUDET L, SCHUBERT HD, GILLARDON F, DAHAN S (2010). Analytical Biochemistry 404: 45-51. 

The BRET2/Arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS).
BERTRAND L, PARENT S, CARON M, LEGAULT M, JOLY E, ANGERS E, BOUVIER M, BROWN M, HOULE B, MÉNARD L (2002). Journal of Receptors and Signal Transduction 22:533-541. 

A cell-based assay for screening the uridine 5(‘)-diphosphate-glucuronosyltransferase 1A inhibitory potential of new chemical entities.
PADROS J, CHUN D, CHEN L, RIGOLLI P, FLARAKOS T, JURIMA-ROMET M (2003).
Anal Biochem. 2003 Sep 15;320(2):310-2. 

Metabolic interactions between low doses of benzo[a]pyrene and tributyltin in arctic charr (Salvelinus alpinus): a long-term in vivo study.
PADROS J, PELLETIER E, RIBEIRO CO (2003).
Toxicol Appl Pharmacol. 2003 Oct 1;192(1):45-55. 

Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET).
ANGERS S, SALAHPOUR A, JOLY E, HILAIRET S, CHELSKY D, DENNIS M, BOUVIER M (2000).
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3684-9. 

Phosphorylation and palmitoylation of the human D2L dopamine receptor in Sf9 cells.
Ng GY, O’DOWD BF, CARON M, DENNIS M, BRANN MR, GEORGE SR (1994).
J Neurochem. 1994 Nov;63(5):1589-95. 

Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor.
Ng GY, MOUILLAC B, GEORGE SR, CARON M, DENNIS M, BOUVIER M, O’DOWD BF (1994).
Eur J Pharmacol. 1994 Mar 15;267(1):7-19. 

Human serotonin1B receptor expression in Sf9 cells: phosphorylation, palmitoylation, and adenylyl cyclase inhibition.
Ng GY, GEORGE SR, ZASTAWNY RL, CARON M, BOUVIER M, DENNIS M, O’DOWD BF (1993).
Biochemistry. 1993 Nov 2;32(43):11727-33. 

Agonist-modulated palmitoylation of beta 2-adrenergic receptor in Sf9 cells.
MOUILLAC B, CARON M, BONIN H, DENNIS M, BOUVIER M (1992).
J Biol Chem. 1992 Oct 25;267(30):21733-7. 

Baculovirus expression of mammalian G protein alpha subunits.
LABRECQUE J, CARON M, TOROSSIAN K, PLAMONDON J, DENNIS M (1992).
FEBS Lett. 1992 Jun 15;304(2-3):157-62